Drug encapsulated nanocarriers are vehicles to transport the drug molecules and release them at the immediate vicinity of the diseased sites. The aim of this study was to design poly (2-hydroxyethyl methacrylate) nanoparticles (PHEMANPs) as a swelling and diffusion controlled drug release system for achieving sustained release of (cis-dichlorodiamminoplatinum II) CDDP. The study undertakes designing and characterization of nanocarriers, optimization of drug encapsulation, and investigating release dynamics of the CDDP drug. PHEMANPs were prepared by suspension polymerization method followed by post loading of the CDDP onto the nanocarriers. The physicochemical and biopharmaceutical properties were evaluated by FTIR, TEM, FESEM, EDX, DLS, surface charge, water intake studies, in vitro cytotoxicity, protein adsorption and percent haemolysis. Chemical stability of the drug was assessed and in vitro release experiments were performed to optimize formulation by UV spectral analysis. The obtained cumulative release data were fitted to zero, first and Korsmeyer-Peppas kinetic models to gain insights into release kinetics and prevailing drug transport mechanisms. The successful encapsulation of CDDP was achieved in different PHEMANP formulations with maximum drug encapsulation efficiency of approx. 60% and the release kinetics was found to follow the Korsmeyer-Peppas model having non-Fickian mechanism. The results indicated that the CDDP can be formulated with a high payload of PHEMANPs which can serve as promising nanomedicine and help in achieving sustained delivery of drug for targeting tumour.